A recent review summarizes predictive biomarkers for HCC prognosis and response to immune therapy, including PD-L1 expression in tumor cells, DNA Damage Repair pathways expression, tumor mutational burden, and tumor-infiltrating lymphocytes [19]. The gene discussed is CD274; the disease is neoplasm.